John Persinos Mar 2, 2017 11:45 AM EST The fact is, after a series of ballot initiatives and legislative actions in states throughout the country, more than half of America now has the right to imbibe marijuana . Hyperbole from Spicer and even Sessions won’t reverse all of those marijuana-friendly laws and regulations. Which brings us to GW Pharmaceuticals ( GWPH ) , a UK-based biopharmaceutical company that’s the best-of-breed stock to profit from the fast rise of the medicinal marijuana industry. Lots of over-hyped penny stocks have sprouted up in the canna-business space and you should be wary of them. GW Pharmaceuticals is a far more stable marijuana company, Medical marijuana however. With a market cap of $3.26 billion, GW Pharmaceuticals is the largest independent company in the medical pot industry. The company develops and markets much-needed cannabinoid prescription medicines, which means that it probably would continue to sell its products even if there is a push-back against recreational marijuana use under a Trump administration. The company’s chief product is Sativex, an oromucosal spray for the treatment of multiple sclerosis, cancer pain and neuropathic pain, ailments for which doctor’s are urgently seeking non-opioid solutions. GW Pharmaceuticals has a partnership with German-based giant Bayer ( BAYRY ) for the distribution of Sativex in the UK. GWPH offers another cannabis-based product, Epidiolex, for the treatment of epilepsy.
To read more visit https://www.thestreet.com/story/14024196/2/trump-s-anti-pot-stance-won-t-hurt-this-canna-business-stock.html